Already have an account?

Login with an existing Projects In Knowledge account
New to Projects In Knowledge?

Register today to customize your experience.
Log In
Don't have an account yet? Click here to register

Register for Free
Already have an account? Click here to log in

Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.

Forgot Password

Please Enter your email address.

  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact

Revision date: This policy was last updated on September 30, 2003.

Education Initiative in Neurology

  • ALS — Investigational Orphan Drug Reduces Need for Durable Medical Equipment in ALS Patients – BreakingMED
  • Patients with amyotrophic lateral sclerosis (ALS) treated with reldesemtiv may have a lower risk and delayed need for durable medical equipment, such as those prescribed for impaired mobility, breathing, swallowing, or speaking, according to results of an analysis of data from the FORTITUDE-ALS study.
    V. Abramson, MD
  • Multiple Sclerosis — Switching DMT in a Patient With RRMS With Injection Fatigue – @Point of Care Chapter
  • Injection fatigue is common in patients taking injectable disease-modifying therapies (DMTs) for multiple sclerosis and may lead to poor adherence. Alternatives to injectable DMTs include oral and intravenous options. Join Dr. James Bowen as he reviews the case of a patient with relapsing remitting MS who has ... more >>
  • Multiple Sclerosis — Covid-19 Data Reassuring for MS, Ulcerative Colitis Patients on Ozanimod – BreakingMED
  • People with multiple sclerosis (MS) or ulcerative colitis (UC) who were infected with SARS-CoV-2 while being treated with ozanimod had Covid outcomes similar to the general population, researchers found, and the majority did not need to stop ozanimod treatment.
    K. Rodowicz, DO
  • Multiple Sclerosis — CMSC: Dimethyl Fumarate Shows Real-World Benefit in Black, Hispanic MS Patients – BreakingMED
  • Dimethyl fumrate continued to show real-world benefits in Black/African American and Hispanic/Latino American patients with relapsing-remitting multiple sclerosis (MS), data from the prospective ESTEEM study showed.
    K. Rodowicz, DO
  • Multiple Sclerosis — CMSC: Extended Natalizumab Dosing Interval in MS Shows Consistent Patient-Reported Outcomes – BreakingMED
  • Among patients with relapsing-remitting multiple sclerosis (MS), patient-reported outcomes were similar whether natalizumab was given at a dosing interval of every 6 weeks or every 4 weeks, according to an analysis of NOVA trial data.
    V. Abramson, MD
  • Multiple Sclerosis — Improving Cognition and Depressive Symptoms in MS – @Point of Care Chapter
  • Cognitive impairment is a common symptom of multiple sclerosis (MS) that occurs early in the course of the disease, may occur independent of other neurologic symptoms, and may be overlooked by clinicians. In addition, early cognitive impairment is a strong indicator of future cognitive decline. Thus, it is ... more >>
  • Multiple Sclerosis — Second-Generation S1P Receptor Modulators for the Treatment of Multiple Sclerosis – @Point of Care Chapter
  • Three second-generation sphingosine 1-phosphate (S1P) receptor modulators are now approved for the treatment of MS. Siponimod was approved in 2019, and ozanimod and ponesimod were both approved during the COVID-19 pandemic, in March 2020 and March 2021, respectively. The development of these drugs was ... more >>
  • Multiple Sclerosis — Case Study: Switching to an S1PR Modulator in a Patient With Moderately Active MS and Needle Fatigue – @Point of Care Chapter
  • Patients with multiple sclerosis (MS) who are receiving an injectable disease-modifying therapy (DMT), such as interferon beta-1a or glatiramer acetate, may experience pain, injection site reactions, or tissue atrophy resulting in “needle fatigue.” Oral DMTs indicated for relapsing forms of MS are available. ... more >>
  • ALS — Survival Analysis Reveals Benefit for Investigational ALS Drug – BreakingMED
  • A post-hoc survival analysis of phase II CENTAUR trial data of sodium phenylbutyrate and taurursodiol (PB and TURSO), an investigational drug for amyotrophic lateral sclerosis (ALS), found better results using a different analytic method than intent-to-treat (ITT) analysis. A rank-preserving structural ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — Covid-19 Vaccines and the Patient With Multiple Sclerosis – @Point of Care Chapter
  • Patients with relapsing multiple sclerosis (MS) can have very different disease courses. This case illustrates the real-life clinical scenario of a patient with highly active relapsing MS, illustrating a course that breaks through multiple disease-modifying therapies (DMTs) and considerations for choosing ... more >>
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care is a clinical decision-making tool that provides a streamlined, comprehensive mobile reference for clinicians to obtain information on the diagnosis, treatment and management of Atrial Fibrillation and VTE. It is made up of a progressive series ... more >>
    S. Connolly, MD, FRCPC
  • Parkinson's Disease @Point of Care
  • From 2005 to 2030, the number of patients with Parkinson’s disease is expected to double. Caroline M. Tanner, MD, PhD provides an overview of the epidemiology of Parkinson’s disease and its associated morbidity in this subchapter of the Parkinson’s Disease @POC program.
    R. Hauser, MD, MBA
  • Multiple Sclerosis @Point of Care
  • MS @Point of Care is a clinical decision support platform that provides comprehensive information on the diagnosis, treatment and management of multiple sclerosis, made up of a progressive series of chapters and other learning tools. It provides multimedia offerings, and contextual expansion of content ... more >>
    B. Cohen, MD
    P. Coyle, MD
  • Multiple Sclerosis — Neurology Morning Commute: Getting UP to Speed on Multiple Sclerosis Management – Podcast
  • With the many treatments now available for the treatment of multiple sclerosis (MS), our faculty reviews this impressive therapeutic landscape and discusses how to choose the best ones for the individual MS patient.
  • Multiple Sclerosis — Neurology Morning Commute: Multiple Sclerosis and the S1P Receptor Upgrade – Podcast
  • In this episode, our faculty looks at the latest treatments for multiple sclerosis—the newest sphingosine-1-phosphate receptor modulators. What is their mechanism of action? Which patients would benefit from them, and how are side effects and toxicities managed with these latest treatment options?
  • Multiple Sclerosis — Neurology Morning Commute: Covid-19 Vaccines and Disease-Modifying Treatments for MS – Podcast
  • Are there issues with getting the Covid-19 vaccine and boosters for patients with MS who are on disease-modifying therapies? In this podcast our faculty discuss the safety and efficacy of the vaccines, timing with disease-modifying therapies, and monoclonal antibodies for prevention and treatment.
  • Multiple Sclerosis — Neurology Morning Commute: Covid-19 Vaccines and the Patient with Multiple Sclerosis – Podcast
  • What is the efficacy of Covid-19 vaccines for multiple sclerosis patients? In this podcast our faculty discuss vaccine safety, how vaccines are affected by disease modifying drugs, and the importance of the vaccines and boosters for this patient population.
  • Multiple Sclerosis — Practical Recommendations for MS Treatment at Diagnosis and Through the Long Term – Webcast
  • Several new disease-modifying therapies for the treatment of multiple sclerosis (MS) were approved during the recent pandemic era: ofatumumab, a human anti-CD20 monoclonal antibody, and two sphingosine-1-phosphate receptor modulators, ozanimod and ponesimod. Join Fred D. Lublin, MD, FAAN, FANA, and Patricia K ... more >>
  • Multiple Sclerosis — MS Immunology and the Immunological Basis of MS DMTs – Webcast
  • Multiple sclerosis, an immune-mediated condition of the central nervous system, is managed using disease-modifying therapies (DMTs) with immunomodulatory or immunosuppressive properties. A working knowledge of immunology is critical to better select appropriate therapy for the individual patient and to ... more >>
  • Multiple Sclerosis — Vaccination Considerations in the Patient With MS – Webcast
  • Clinicians have a critical role in ensuring that their patients with multiple sclerosis (MS) are vaccinated against Covid-19 and other transmissible diseases. Patients may be hesitant to receive the vaccine for multiple reasons, however, including concern that vaccination will interfere with their disease- ... more >>
  • ALS — Case Study: Management of a Patient Newly Diagnosed With Amyotrophic Lateral Sclerosis – Case Study
  • Treatment options for amyotrophic lateral sclerosis (ALS) have expanded in recent years with the availability of disease-modifying and symptomatic therapies that can be offered to individuals living with ALS and have the potential to improve the quality and the length of their lives. In addition, ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • ALS — Neurology Morning Commute: New and Emerging Treatments for ALS – Podcast
  • In this podcast our faculty discuss new and emerging treatments for ALS, as well as managing some of the more debilitating symptoms of the disease.
    J. Shefner, MD, PhD, FAAN
  • Alzheimer's Disease — Neurology Journal Club: – Podcast
  • Is amyloid the right target for new Alzheimer’s disease therapies? Will any of these therapies, if they win approval, advance the treatment of Alzheimer’s disease? Our faculty explores these and other questions.
    B. Dickerson, MD
  • ALS — Case Study: Management of a Patient Newly Diagnosed With Amyotrophic Lateral Sclerosis – Case Study
  • Treatment options for amyotrophic lateral sclerosis (ALS) have expanded in recent years with the availability of disease-modifying and symptomatic therapies that can be offered to individuals living with ALS and have the potential to improve the quality and the length of their lives. In addition, ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Managing Highly Active Disease in an RRMS Patient with Worsening on Initial Treatment – Case Study
  • This case illustrates the treatment strategy employed for a RRMS patient who has high MS disease activity despite adherence to first-line injectable disease-modifying therapy. It highlights switching strategies that can be considered for such patients, and reviews safety and efficacy data for approved high- ... more >>
    P. Repovic, MD
  • Multiple Sclerosis — RRMS Patient with Active On-Treatment Disease Considering a Switch to a Selective Oral S1P Inhibitor – Case Study
  • In this case, the diagnosis and initial treatment of a patient with relapsing multiple sclerosis (MS) is reviewed. This illustrates the considerations that occur when a patient has a clinical relapse while on disease-modifying therapy and highlights available and emerging oral therapies for the treatment of ... more >>
    C. Azevedo, MD, MPH
  • Multiple Sclerosis — Case Study: Misdiagnosis in MS – Case Study
  • The 2017 revisions to the McDonald criteria have refined the diagnosis of multiple sclerosis (MS). However, these criteria must only be applied to patients with symptoms typical of demyelination. In addition, there must be "no better explanation." This case follows the skillful navigation of diagnosis in a 56 ... more >>
    A. Solomon, MD
  • Multiple Sclerosis — Risk-Averse RRMS Patient With a Preference for an Oral DMT – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) who has a clinical relapse on his first disease-modifying therapy. It illustrates considerations when switching medications, including patient preference for therapeutic delivery, and ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — Case Study: Patient With Secondary-Progressive MS and Active Disease – Case Study
  • This case study follows a 39-year-old man who developed relapsing-remitting multiple sclerosis (MS) when he was 34. He is being treated with an oral agent for relapsing MS; however he has since advanced to secondary-progressive MS (SPMS) and shows signs of active disease radiographically. New treatment ... more >>
    E. Williamson, MD
  • Multiple Sclerosis — Patient with Active Relapsing MS at High Risk for PML – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) that is following an aggressive clinical course. It illustrates the considerations that should occur when initiating and switching disease modifying therapies (DMTs), as well as highlighting ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — An African American Patient with Increasing Symptoms: Managing a Newly Diagnosed Patient with PPMS – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with primary progressive multiple sclerosis (PPMS). It illustrates the considerations involved in selection of treatment for patients with progressive forms of MS, as well as highlighting the natural course of progressive disease and the ... more >>
    J. Rinker, MD
  • Multiple Sclerosis — A Patient with RRMS Who Experiences Breakthrough Disease on Two Disease-Modifying Therapies – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing-remitting multiple sclerosis (RRMS) who has breakthrough disease activity on her first disease-modifying therapy (DMT) and switches to a different class of DMT. After doing well on her second DMT for awhile, she experiences ... more >>
    J. Bowen, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information